Help Cure ASPS: Sponsor Team ASPS Bike Ride at the Pan-Massachusetts Challenge 2024
Dear ASPS community, Last weekend August 3-4, 2024 Team ASPS rode for the 21st time the Pan-Massachusetts Challenge (PMC). I am asking you to sponsor our 85-mile bike ride and sponsor research at the Dana Farber Cancer Institute that aims to bring more therapies for ASPS. Twenty-one years have passed since my middle daughter was […]
The Rare Cancer Research Foundation is Partnering with iCureASPS: Please Help Find a Cure – Donate Your ASPS Tumor
The Rare Cancer Research Foundation (RCRF) is a 501(c)3 dedicated to curing rare cancers through strategic investments and innovative collaborations that facilitate effective research and accelerate deployment of promising therapies. RCRF initiated Pattern.org. If you are going to have a surgery to remove your Alveolar Soft Part Sarcoma tumor: either your primary tumor or metastatic […]
New Therapeutic Targets in Alveolar Soft Part Sarcoma Described in a New Publication
New Therapeutic Targets in Alveolar Soft Part Sarcoma were revealed in a new study conducted by Dr. Ewa Sicinska from the Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, and Dr. Matt Hemming from the Department of Medicine, Division of Hematology and Oncology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA. […]
iCureASPS is Marking 20 Years of Activity
The first weekend of August 2023 is marking 20 years of iCureASPS efforts to find a cure for Alveolar Soft Part Sarcoma (ASPS). This weekend “Team ASPS” will ride for the 20th time at the PMC bike ride. Please donate and support our efforts to find a cure for ASPS. Through Saturday and Sunday, August […]
FDA Grants Approval to Atezolizumab for Alveolar Soft Part Sarcoma
On December 9, 2022, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS). Efficacy was evaluated in Study ML39345 (NCT03141684), an open-label, single-arm study in 49 adult and pediatric patients with unresectable or […]
Summer 2022: Updated Clinical Research on Alveolar Soft Part Sarcoma
Below are links to eighteen publications describing clinical studies of ASPS with novel treatments as well as preclinical information on ASPS. The ASPS community is thankful to all the Principle Investigators, Oncologists and Researchers who are working with us to find a cure for ASPS! Anlotinib with Toripalimab for ASPS Therapy Complete Response of Metastatic […]
Please Support “Team ASPS” 2022 PMC Bike Ride at The PMC in Search for Cure
Dear Friends, On Saturday and Sunday August 6 and 7th, 2022, Team ASPS will ride for the 19th time the Pan-Massachusetts Challenge (PMC) bike ride. This year our team includes six riders! We are raising donations and riding to find a cure for Alveolar Soft Part Sarcoma (ASPS). ASPS is a rare cancer that tends […]
Please donate to support Team ASPS efforts to find a cure for Alveolar Soft Part Sarcoma: 2021 PMC bike ride
Update: On August the 8th, 2021, Team ASPS Completed the PMC Bike Ride of 100 Miles, the Fundraising to support ASPS Research at the Dana Farber Cancer Institute in Boston is On-going. Please donate, and read more below”. Dear Friends, On August 7-8th, Team ASPS will ride for the 18th time on the Pan-Massachusetts Challenge […]
Phase 2 Clinical Trial for Alveolar Soft Part Sarcoma Patients: Testing Atezolizumab, A Study by the NCI
Dear ASPS community, please read the recent update of this clinical trial from September 2020: This is a Phase II clinical study testing the ability of the anti-PD-L1 antibody, Atezolizumab, in treating patients with ASPS that has spread to other parts of the body and cannot be removed by surgery. The FDA granted Breakthrough Therapy Designation […]
2019 Progress Report on Alveolar Soft Part Sarcoma – American Society of Clinical Oncology (ASCO) annual meeting
We selected to highlight 3 studies that were presented this year at the ASCO conference: 1. Treatment of ASPS with anlotinib (a new oral tyrosine kinase inhibitor therapy), Clinical trial information: NCT02449343 2. Combination treatment of ASPS with NKTR214 (immune modulator) and nivolumab (immune checkpoint inhibitor), Clinical trial information: NCT03282344 3. Successful generation of patient-derived xenografts and cell […]